About: Adaptive immunity: an emerging player in the progression of NAFLD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adaptive immunity: an emerging player in the progression of NAFLD Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Adaptive immunity: an emerging player in the progression of NAFLD
Creator	Albano, Emanuele Sutti, Salvatore
topic	covid:16976001fa279f5abf009f364117db0073937df9#this
Source	PMC
abstract	In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease and cirrhosis, as well as an important risk factor for hepatocellular carcinoma (HCC). NAFLD encompasses a spectrum of liver lesions, including simple steatosis, steatohepatitis and fibrosis. Although steatosis is often harmless, the lobular inflammation that characterizes nonalcoholic steatohepatitis (NASH) is considered a driving force in the progression of NAFLD. The current view is that innate immune mechanisms represent a key element in supporting hepatic inflammation in NASH. However, increasing evidence points to the role of adaptive immunity as an additional factor promoting liver inflammation. This Review discusses data regarding the role of B cells and T cells in sustaining the progression of NASH to fibrosis and HCC, along with the findings that antigens originating from oxidative stress act as a trigger for immune responses. We also highlight the mechanisms affecting liver immune tolerance in the setting of steatohepatitis that favour lymphocyte activation. Finally, we analyse emerging evidence concerning the possible application of immune modulating treatments in NASH therapy.
has issue date	2019-10-11(xsd:dateTime)
bibo:doi	10.1038/s41575-019-0210-2
bibo:pmid	31605031
has license	no-cc
sha1sum (hex)	16976001fa279f5abf009f364117db0073937df9
schema:url	https://doi.org/10.1038/s41575-019-0210-2
resource representing a document's title	Adaptive immunity: an emerging player in the progression of NAFLD
has PubMed Central identifier	PMC7222953
has PubMed identifier	31605031
schema:publication	Nat Rev Gastroenterol Hepatol
resource representing a document's body	covid:16976001fa279f5abf009f364117db0073937df9#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/16976001fa279f5abf009f364117db0073937df9
is schema:about of	named entity 'antigens' named entity 'NASH' named entity 'progression' named entity 'NASH' named entity 'fibrosis' named entity 'encompasses' named entity 'T CELLS' named entity 'SIMPLE STEATOSIS' named entity 'LIVER' named entity 'POINTS' named entity 'INCREASING' named entity 'FACTOR' named entity 'driving force' named entity 'However' named entity 'Review' named entity 'B cells' named entity 'data' named entity 'emerging' named entity 'nonalcoholic fatty liver disease' named entity 'factor' named entity 'progression' named entity 'steatosis' named entity 'current view' named entity 'nonalcoholic steatohepatitis' named entity 'immune tolerance' named entity 'nonalcoholic fatty liver disease' named entity 'antigens' named entity 'lymphocyte activation' named entity 'liver inflammation' named entity 'Adaptive immunity' named entity 'mechanisms' named entity 'evidence' named entity 'chronic liver disease' named entity 'chronic liver' named entity 'liver' named entity 'parenchymal' named entity 'adaptive immunity' named entity 'oxidative stress' named entity 'cirrhosis' named entity 'mouse models' named entity 'ligation' named entity 'NKT' named entity 'immune tolerance' named entity 'belimumab' named entity 'control individuals' named entity 'steatosis' named entity 'phase II clinical trial' named entity 'liver' named entity 'NKT' named entity 'choline' named entity 'IL-15' named entity 'carcinogen' named entity 'steatohepatitis' named entity 'IFNγ' named entity 'hepatocyte' named entity 'NASH' named entity 'CD80' named entity 'IgM' named entity 'immune mechanisms' named entity 'NASH' named entity 'pathogenesis' named entity 'antibody' named entity 'IL-17' named entity 'oxidative stress' named entity 'IgM' named entity 'phase II clinical trial' named entity 'evolution' named entity 'liver injury' named entity 'inflammation' named entity 'NASH' named entity 'innate immunity' named entity 'NAFLD' named entity 'liver' named entity 'Rag1' named entity 'cell differentiation' named entity 'Kupffer cells' named entity 'lipid peroxidation' named entity 'LCN2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software